- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01392378
Study Assessing the Effect of Medications to Prevent Fever on Prevenar 13®
January 10, 2014 updated by: Pfizer
A Phase 4, Randomized, Open-Label Trial To Assess The Impact Of Prophylactic Antipyretic Medication On The Immunogenicity Of 13-Valent Pneumococcal Conjugate Vaccine Given With Routine Pediatric Vaccinations In Healthy Infants
The purposes of this study are assess the immunological response (measure the amount of antibodies, i.e. proteins that fight off germs) produced by children after they have been given the 13-valent pneumococcal vaccine (13vPnC) and INFANRIX hexa at 2, 3, 4 and 12 months of age when medications to prevent fever are given on the same day as the vaccination.
Also to evaluate the safety of 13-valent pneumococcal conjugate vaccine (13vPnC) in children who receive medications to prevent fever on the day of vaccination.
Study Overview
Status
Completed
Conditions
Study Type
Interventional
Enrollment (Actual)
908
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Debica, Poland, 39-200
- Gabinet Lekarski
-
Krakow, Poland, 31-302
- Hanna Czajka Indywidualna Praktyka Lekarska
-
Krakow, Poland, 31-422
- NZOZ "Praktimed" sp. z o.o.
-
Leczna, Poland, 21-010
- NZOZ Salmed
-
Lodz, Poland, 91-347
- Specjalistyczna Praktyka Lekarska GRAVITA
-
Lubartow, Poland, 21-100
- SP ZOZ Lubartow
-
Lublin, Poland, 20-044
- NZOZ Praktyka Lekarza Rodzinnego Eskulap
-
Oborniki Slaskie, Poland, 55-120
- NZOZ Praktyka Lekarza Rodzinnego Alina Grocka-Wlazlak
-
Poznan, Poland, 61-734
- Specjalistyczny ZOZ nad Matka i Dzieckiem, Oddzial Obserwacyjno Zakazny A, Szpital Dzieciecy
-
Siemianowice Slaskie, Poland, 41-103
- NZLA Michalkowice Jarosz i Partnerzy
-
Torun, Poland, 87-100
- NZOZ Nasz Lekarz
-
Trzebnica, Poland, 55-100
- Szpital im. Sw. Jadwigi Slaskiej, Oddzia Pediatryczny
-
Warszawa, Poland, 02-127
- DEN-MED Gabinet Lekarsko-Stomatologiczny Joanna i Jacek Witwiccy
-
Wroclaw, Poland, 50-345
- Samodzielny Publiczny Szpital Kliniczny Nr 1 we Wroclawiu
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
1 year to 1 year (Child)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Aged 2 months (56 to 98 days) at time of enrollment.
- Healthy infant as determined by medical history, physical examination, and judgment of the investigator.
Exclusion Criteria:
- Previous vaccination with licensed or investigational pneumococcal, diphtheria, tetanus, pertussis, polio, or Hib conjugate vaccines.
- A previous anaphylactic reaction to any vaccine or vaccine-related component.
- Allergy or contraindication to paracetamol or ibuprofen administration.
- Contraindication to vaccination with pneumococcal conjugate, diphtheria, tetanus, pertussis, polio, Hib, or HBV vaccines.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Group 1
Subjects will receive 13-valent pneumococcal vaccine and INFANRIX hexa at 2, 3, 4 and 12 months of age.
They will also receive 2 doses of paracetamol on the day of each vaccination.
|
13vPnC will be administered by intramuscular injection at 2, 3, 4 and 12 months of age.
INFANRIX hexa will be administered by intramuscular injection at 2, 3, 4 and 12 months of age.
Paracetamol suspension for oral administration will be given at a weight adjusted dose of 15mg/kg/dose.
The first dose will be given 6-8 hours after each vaccination, the second dose to be given 6-8 hours after the first.
Paracetamol suspension for oral administration will be given at a weight adjusted dose of 15mg/kg/dose.
The first dose will be given at the time of each vaccination, the second dose to be given 6-8 hours after the first, and the third dose to be given 6-8 hours after the second.
|
Experimental: Group 2
Subjects will receive 13-valent pneumococcal vaccine and INFANRIX hexa at 2, 3, 4 and 12 months of age.
They will also receive 2 doses of ibuprofen on the day of each vaccination.the
first dose.
|
13vPnC will be administered by intramuscular injection at 2, 3, 4 and 12 months of age.
INFANRIX hexa will be administered by intramuscular injection at 2, 3, 4 and 12 months of age.
Ibuprofen suspension for oral administration will be given at a weight adjusted dose of 10mg/kg/dose.
The first dose will be given 6-8 hours after each vaccination, the second dose to be given 6-8 hours after the first.
Ibuprofen suspension for oral administration will be given at a weight adjusted dose of 10mg/kg/dose.
The first dose will be given at the time of each vaccination, the second dose to be given 6-8 hours after the first, and the third dose to be given 6-8 hours after the second.
|
Experimental: Group 3
Subjects will receive 13-valent pneumococcal vaccine and INFANRIX hexa at 2, 3, 4 and 12 months of age.
They will also receive 3 doses of paracetamol on the day of each vaccination.
|
13vPnC will be administered by intramuscular injection at 2, 3, 4 and 12 months of age.
INFANRIX hexa will be administered by intramuscular injection at 2, 3, 4 and 12 months of age.
Paracetamol suspension for oral administration will be given at a weight adjusted dose of 15mg/kg/dose.
The first dose will be given 6-8 hours after each vaccination, the second dose to be given 6-8 hours after the first.
Paracetamol suspension for oral administration will be given at a weight adjusted dose of 15mg/kg/dose.
The first dose will be given at the time of each vaccination, the second dose to be given 6-8 hours after the first, and the third dose to be given 6-8 hours after the second.
|
Experimental: Group 4
Subjects will receive 13-valent pneumococcal vaccine and INFANRIX hexa at 2, 3, 4 and 12 months of age.
They will also receive 3 doses of ibuprofen on the day of each vaccination.
|
13vPnC will be administered by intramuscular injection at 2, 3, 4 and 12 months of age.
INFANRIX hexa will be administered by intramuscular injection at 2, 3, 4 and 12 months of age.
Ibuprofen suspension for oral administration will be given at a weight adjusted dose of 10mg/kg/dose.
The first dose will be given 6-8 hours after each vaccination, the second dose to be given 6-8 hours after the first.
Ibuprofen suspension for oral administration will be given at a weight adjusted dose of 10mg/kg/dose.
The first dose will be given at the time of each vaccination, the second dose to be given 6-8 hours after the first, and the third dose to be given 6-8 hours after the second.
|
Experimental: Group 5
Subjects will receive 13-valent pneumococcal vaccine and INFANRIX hexa at 2, 3, 4 and 12 months of age.
This group does not receive any antipyretic medication as part of the study.
|
13vPnC will be administered by intramuscular injection at 2, 3, 4 and 12 months of age.
INFANRIX hexa will be administered by intramuscular injection at 2, 3, 4 and 12 months of age.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Geometric Mean Concentration (GMC) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody 1 Month After the Infant Series
Time Frame: 1 month after the infant series
|
Antibody geometric least squares (LS) mean concentrations (GMCs) for 13 pneumococcal serotypes (4, 6B, 9V, 14, 18C, 19F, 23F, 1, 3, 5, 6A, 7F and 19A) are presented.
GMC (13vPnC) and corresponding 2-sided 95 percent (%) confidence interval (CI) were evaluated.
Geometric means (GMs) were calculated using all participants with available data for the specified blood draw.
Here 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure and 'n' signifies participants with a determinate IgG concentration to the given serotype for each arm, respectively.
|
1 month after the infant series
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Participants Achieving Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody Level Greater Than or Equal to (>=)0.35 Microgram Per Milliliter (Mcg/mL) 1 Month After the Infant Series
Time Frame: 1 month after the infant series
|
Percentage of participants achieving predefined antibody threshold >=0.35 mcg/mL along with the corresponding 95% confidence interval (CI) for 13 pneumococcal serotypes (4, 6B, 9V, 14, 18C, 19F, 23F, 1, 3, 5, 6A, 7F and 19A) are presented.
Exact 2-sided CI based on the observed proportion of participants.
|
1 month after the infant series
|
Geometric Mean Concentration (GMC) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody 1 Month After the Toddler Dose
Time Frame: 1 month after the toddler dose
|
Antibody geometric LS mean concentrations (GMCs) for 13 pneumococcal serotypes (4, 6B, 9V, 14, 18C, 19F, 23F, 1, 3, 5, 6A, 7F and 19A) are presented.
GMC (13vPnC) and corresponding 2-sided 95% CI were evaluated.
Geometric means (GMs) were calculated using all participants with available data for the specified blood draw.
Here 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure and 'n' signifies participants with a determinate IgG concentration to the given serotype for each arm respectively.
|
1 month after the toddler dose
|
Percentage of Participants Achieving Serotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) Titers Greater Than or Equal to (>=) Lower Limit of Quantitation (LLOQ) 1 Month After the Infant Series
Time Frame: 1 month after the infant series
|
Percentage of participants achieving serotype-specific pneumococcal OPA titer >= LLOQ, along with the corresponding 95% CIs for 13 pneumococcal serotypes (4, 6B, 9V, 14, 18C, 19F, 23F, 1, 3, 5, 6A, 7F and 19A) are presented.
Exact 2-sided CI based on the observed proportion of participants.
The OPA LLOQ in titers for each serotype: 1 = 1:18; 3 = 1:12; 4 = 1:21; 5 = 1:29; 6A = 1:37; 6B = 1:43; 7F = 1:210; 9V = 1:345; 14 = 1:35; 18C = 1:31; 19A = 1:18; 19F = 1:48; 23F = 1:13.
|
1 month after the infant series
|
Geometric Mean Titer (GMT) for Serotype-specific Pneumococcal Opsonophagocytic Activity (OPA) 1 Month After the Infant Series
Time Frame: 1 month after the infant series
|
Antibody-mediated serum OPA against the 13 pneumococcal serotypes (4, 6B, 9V, 14, 18C, 19F, 23F, 1, 3, 5, 6A, 7F and 19A) was measured centrally using a pneumococcal OPA assay.
Results were expressed as OPA titers.
OPA titers were logarithmically transformed for analysis; geometric means calculated and expressed as geometric mean titers (GMTs).
|
1 month after the infant series
|
Geometric Mean Concentration (GMC) for Antigen-specific Haemophilus Influenzae Type b (Hib) Polyribosylribitol Phosphate (PRP) Antibody 1 Month After the Infant Series
Time Frame: 1 month after the infant series
|
Geometric LS mean concentrations (GMCs) and corresponding 2-sided 95% CIs were evaluated for Hib PRP antibody.
|
1 month after the infant series
|
Geometric Mean Concentration (GMC) for Antigen-specific Pertussis Toxin (PT), Filamentous Hemagglutinin (FHA) and Pertactin (PRN) Antibody 1 Month After the Infant Series
Time Frame: 1 month after the infant series
|
Geometric LS mean concentration (GMCs) were measured in Enzyme-linked Immunosorbent Assay (ELISA) units/mL (EU/mL) and corresponding 2-sided 95% CIs were evaluated for pertussis (pertussis toxin [PT], filamentous hemagglutinin [FHA] and pertactin [PRN]) antibodies.
|
1 month after the infant series
|
Geometric Mean Concentration (GMC) for Antigen-specific Tetanus and Diphtheria Antibody 1 Month After the Infant Series
Time Frame: 1 month after the infant series
|
Geometric LS mean concentration (GMCs) were measured in International Units/mL (IU/mL) and corresponding 2-sided 95% CIs were evaluated for tetanus and diphtheria antibodies.
|
1 month after the infant series
|
Geometric Mean Concentration (GMC) for Antigen-specific Hepatitis B Virus (HBV) Antibody 1 Month After the Infant Series
Time Frame: 1 month after the infant series
|
Geometric LS mean concentration (GMCs) were measured in milli international units/mL (mIU/mL) and corresponding 2-sided 95% CIs were evaluated for hepatitis B virus (HBV) antibody.
|
1 month after the infant series
|
Geometric Mean Titer (GMT) for Antigen-specific Poliomyelitis Type 1, 2 and 3 Antibodies 1 Month After the Infant Series
Time Frame: 1 month after the infant series
|
Geometric LS mean concentrations (GMCs) were measured as titers and corresponding 2-sided 95% CIs were evaluated for poliomyelitis type 1, 2 and 3 antibodies.
|
1 month after the infant series
|
Geometric Mean Concentration (GMC) for Antigen-specific Haemophilus Influenzae Type b (Hib) Polyribosylribitol Phosphate (PRP) Antibody 1 Month After the Toddler Dose
Time Frame: 1 month after the toddler dose
|
Geometric LS mean concentration (GMCs) were measured in mcg/mL and corresponding 2-sided 95% CIs were evaluated for Hib PRP antibody.
|
1 month after the toddler dose
|
Geometric Mean Concentration (GMC) for Antigen-specific Pertussis Toxin (PT), Filamentous Hemagglutinin (FHA) and Pertactin (PRN) Antibodies 1 Month After the Toddler Dose
Time Frame: 1 month after the toddler dose
|
Geometric LS mean concentration (GMCs) were measured in EU/mL and corresponding 2-sided 95% CIs were evaluated for pertussis (pertussis toxin [PT], filamentous hemagglutinin [FHA] and pertactin [PRN]) antibodies.
|
1 month after the toddler dose
|
Geometric Mean Concentration (GMC) for Antigen-specific Tetanus and Diphtheria Antibodies 1 Month After the Toddler Dose
Time Frame: 1 month after the toddler dose
|
Geometric LS mean concentration (GMCs) were measured in IU/mL and corresponding 2-sided 95% CIs were evaluated for tetanus and diphtheria antibodies.
|
1 month after the toddler dose
|
Geometric Mean Concentration (GMC) for Antigen-specific Hepatitis B Virus (HBV) Antibody 1 Month After the Toddler Dose
Time Frame: 1 month after the toddler dose
|
Geometric LS mean concentration (GMCs) were measured in mIU/mL and corresponding 2-sided 95% CIs were evaluated for hepatitis B virus (HBV) antibody.
|
1 month after the toddler dose
|
Geometric Mean Titer (GMT) for Antigen-specific Poliomyelitis Type 1, 2 and 3 Antibodies 1 Month After the Toddler Dose
Time Frame: 1 month after the toddler dose
|
Geometric LS mean concentration (GMCs) were measured as titers and corresponding 2-sided 95% CIs were evaluated for poliomyelitis type 1, 2 and 3 antibodies.
|
1 month after the toddler dose
|
Percentage of Participants Achieving Pre-specified Criteria for the Concomitant Antigens Contained in INFANRIX Hexa 1 Month After the Infant Series
Time Frame: 1 month after the infant series
|
Percentage of participants achieving pre-specified criteria for concomitant antigens contained in INFANRIX hexa (Hib polyribosylribitol phosphate [PRP] >=0.15 mcg/mL; Hib PRP >=1 mcg/mL; Pertussis PT >=14.6 EU/mL, FHA >=16.1 EU/mL, PRN >=24.0
EU/mL; Tetanus >=0.1 IU/mL; Diphtheria >=0.1 IU/mL; HBV >=10 mIU/mL; Poliomyelitis Type 1, 2, 3 >=1:8 titer) along with the corresponding 95% CIs were presented.
Exact 2-sided CI based on the observed proportion of participants.
Pre-specified criteria for pertussis was the level that 95% of the participants achieved in 13vPnC + INFANRIX hexa group.
|
1 month after the infant series
|
Percentage of Participants Achieving Pre-specified Criteria for the Concomitant Antigens Contained in INFANRIX Hexa 1 Month After the Toddler Dose
Time Frame: 1 month after the toddler dose
|
Percentage of participants achieving pre-specified criteria for concomitant antigens contained in INFANRIX hexa (Hib polyribosylribitol phosphate [PRP] >=0.15 mcg/mL; Hib PRP >=1 mcg/mL; Pertussis PT >=14.8
EU/mL, FHA >=46.5 EU/mL, PRN >=43.5 EU/mL; Tetanus >=0.1 IU/mL; Diphtheria >=0.1 IU/mL; HBV >=10 mIU/mL; Poliomyelitis Type 1, 2, 3 >=1:8 titer) along with the corresponding 95% CIs were presented.
Exact 2-sided CI based on the observed proportion of participants.
Pre-specified criteria for pertussis was the level that 95% of the participants achieved in 13vPnC + INFANRIX hexa group.
|
1 month after the toddler dose
|
Percentage of Participants Reporting Fever Within 4 Days: Infant Series Dose 1
Time Frame: Within 4 days after infant series Dose 1
|
Participants' core (rectal) temperature was collected for 4 days after each vaccination using an electronic diary.
Participants' temperature was collected at 6 to 8 hours after vaccination, 6 to 8 hours following that and coincidentally with antipyretic administration for groups receiving antipyretics.
Temperature was recorded at bedtime daily for 3 following days (Day 2 to Day 4) and at any time during the 3 days when fever was suspected.
The highest temperature for each day was recorded in the e-diary.
Incidences of fever were presented in following categories: >=38 but <=39 degree Celsius (degree C), greater than (>) 39 but <=40 degree C and >40 degree C.
|
Within 4 days after infant series Dose 1
|
Percentage of Participants Reporting Fever Within 4 Days: Infant Series Dose 2
Time Frame: Within 4 days after infant series Dose 2
|
Participants' rectal temperature was collected for 4 days after each vaccination using an electronic diary.
Participants' temperature was collected at 6 to 8 hours after vaccination, 6 to 8 hours following that and coincidentally with antipyretic administration for groups receiving antipyretics.
Temperature was recorded at bedtime daily for 3 following days (Day 2 to Day 4) and at any time during the 3 days when fever was suspected.
The highest temperature for each day was recorded in the e-diary.
Incidences of fever were presented in following categories: >=38 but <=39 degree C, >39 but <=40 degree C and >40 degree C.
|
Within 4 days after infant series Dose 2
|
Percentage of Participants Reporting Fever Within 4 Days: Infant Series Dose 3
Time Frame: Within 4 days after infant series Dose 3
|
Participants' rectal temperature was collected for 4 days after each vaccination using an electronic diary.
Participants' temperature was collected at 6 to 8 hours after vaccination, 6 to 8 hours following that and coincidentally with antipyretic administration for groups receiving antipyretics.
Temperature was recorded at bedtime daily for 3 following days (Day 2 to Day 4) and at any time during the 3 days when fever was suspected.
The highest temperature for each day was recorded in the e-diary.
Incidences of fever were presented in following categories: >=38 but <=39 degree C, >39 but <=40 degree C and >40 degree C. Report of fever >40 degrees C after 13vPnC Infant Series Dose 3 was confirmed as data entry error.
|
Within 4 days after infant series Dose 3
|
Percentage of Participants Reporting Fever Within 4 Days: Toddler Dose
Time Frame: Within 4 days after toddler dose
|
Participants' rectal temperature was collected for 4 days after each vaccination using an electronic diary.
Participants' temperature was collected at 6 to 8 hours after vaccination, 6 to 8 hours following that and coincidentally with antipyretic administration for groups receiving antipyretics.
Temperature was recorded at bedtime daily for 3 following days (Day 2 to Day 4) and at any time during the 3 days when fever was suspected.
The highest temperature for each day was recorded in the e-diary.
Incidences of fever were presented in following categories: >=38 but <=39 degree C, >39 but <=40 degree C and >40 degree C.
|
Within 4 days after toddler dose
|
Number of Participants With Non-Serious Adverse Events (AEs) and Serious Adverse Events (SAEs): Infant Series
Time Frame: Baseline up to 1 Month (28 to 42 days) after infant series
|
An AE was any untoward medical occurrence in a participant who received vaccine without regard to possibility of causal relationship.
SAE: an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial/prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.
Treatment-emergent events for infant series were events between infant series Dose 1 and up to 1 month (28 to 42 days) after infant series that were absent before treatment or that worsened relative to pre-treatment state.
Reported non-SAEs included AEs other than SAEs collected using electronic diary (fever, systematic assessment) and events spontaneously collected on case report form at each visit (non-systematic assessment).
|
Baseline up to 1 Month (28 to 42 days) after infant series
|
Number of Participants With Non-Serious Adverse Events (AEs) and Serious Adverse Events (SAEs): After the Infant Series
Time Frame: 1 Month (28 to 42 days) after infant series Dose 3 up to toddler dose
|
An AE was any untoward medical occurrence in a participant who received vaccine without regard to possibility of causal relationship.
SAE: an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial/prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.
Treatment-emergent events after the infant series were events between 1 month (28 to 42 days) after infant series to toddler dose that were absent before treatment or that worsened relative to pre-treatment state.
Reported non-SAEs included AEs other than SAEs spontaneously collected on case report form (non-systematic assessment).
|
1 Month (28 to 42 days) after infant series Dose 3 up to toddler dose
|
Number of Participants With Non-Serious Adverse Events (AEs) and Serious Adverse Events (SAEs): Toddler Dose
Time Frame: Toddler dose up to 1 Month (28 to 42 days) after toddler dose
|
An AE was any untoward medical occurrence in a participant who received vaccine without regard to possibility of causal relationship.
SAE: an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial/prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.
Treatment-emergent events for toddler dose were events between toddler dose and up to 1 month (28 to 42 days) after toddler dose that were absent before treatment or that worsened relative to pre-treatment state.
Reported non-SAEs included AEs other than SAEs collected using electronic diary (fever, systematic assessment) and events spontaneously collected on case report form at each visit (non-systematic assessment).
|
Toddler dose up to 1 Month (28 to 42 days) after toddler dose
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
August 1, 2011
Primary Completion (Actual)
January 1, 2013
Study Completion (Actual)
January 1, 2013
Study Registration Dates
First Submitted
July 8, 2011
First Submitted That Met QC Criteria
July 8, 2011
First Posted (Estimate)
July 12, 2011
Study Record Updates
Last Update Posted (Estimate)
February 26, 2014
Last Update Submitted That Met QC Criteria
January 10, 2014
Last Verified
January 1, 2014
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Cyclooxygenase Inhibitors
- Antipyretics
- Immunologic Factors
- Vaccines
- Heptavalent Pneumococcal Conjugate Vaccine
- Acetaminophen
- Ibuprofen
Other Study ID Numbers
- B1851047
- 6096A1-4027
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pneumococcal Vaccines
-
Wyeth is now a wholly owned subsidiary of PfizerCompletedVaccines, Pneumococcal | Vaccines, Pneumococcal Conjugate Vaccine
-
Vaxcyte, Inc.CompletedPneumococcal VaccinesUnited States
-
Wyeth is now a wholly owned subsidiary of PfizerCompletedVaccines, PneumococcalGermany
-
Wyeth is now a wholly owned subsidiary of PfizerCompletedPneumococcal VaccinesUnited States
-
PfizerCompletedPneumococcal Vaccines | Pneumococcal Conjugate VaccineJapan
-
VA Sierra Nevada Health Care SystemMerck Sharp & Dohme LLCNot yet recruitingImmunosuppression | Pneumococcal Vaccines
-
Maria de Lourdes de Sousa Maia, MDNot yet recruiting
-
Vaxcyte, Inc.Active, not recruitingPneumococcal VaccinesUnited States
-
Inventprise Inc.PATH; Canadian Center for Vaccinology; Vaccine Evaluation Center, CanadaActive, not recruitingPneumococcal VaccinesCanada
-
Inventprise Inc.PATH; Canadian Center for Vaccinology; Vaccine Evaluation Center, CanadaCompletedPneumococcal VaccinesCanada
Clinical Trials on 13-valent pneumococcal conjugate vaccine
-
Beijing Zhifei Lvzhu Biopharmaceutical Co., LtdRecruitingConsistency, Immunogenicity, and Safety of Three Batches of 15-valent Pneumococcal Conjugate VaccineHealthy VolunteersChina
-
Sinovac Life Sciences Co., Ltd.RecruitingPneumococcal InfectionsChina
-
Beijing Zhifei Lvzhu Biopharmaceutical Co., LtdNot yet recruiting
-
Wyeth is now a wholly owned subsidiary of PfizerCompletedPneumococcal VaccineKorea, Republic of
-
Murdoch Childrens Research InstituteNational Health and Medical Research Council, Australia; GlaxoSmithKline; Bill... and other collaboratorsCompleted
-
Wyeth is now a wholly owned subsidiary of PfizerCompletedVaccines, PneumococcalGermany
-
CanSino Biologics Inc.Henan Center for Disease Control and PreventionCompletedPneumococcal Infections | Bacterial Infections | Streptococcal InfectionsChina
-
Telethon Kids InstitutePapua New Guinea Institute of Medical ResearchCompleted
-
PfizerCompletedPneumococcal DiseaseSpain, Poland, Hungary
-
Wyeth is now a wholly owned subsidiary of PfizerCompletedVaccines, PneumococcalSpain